NEWS AND EVENTS
NEWS AND EVENTS
Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020
Four presentations at oral and ePoster sessions focus on the effect of SNF472 in vascular calcification disorders Palma, Spain and San Diego, USA, October 22, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announced the presentation of new data on lead candidate SNF472 today at […]
Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020
Palma, Spain and San Diego, USA, October 12, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020. Sanifit will make […]
Sanifit Appoints Adam Levy as Chief Financial Officer
Palma, Spain and San Diego, USA, 20 August 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced the appointment of Adam Levy as Chief Financial Officer, with immediate effect. Mr. Levy was most recently with Brickell Biotech where he served as Chief Business Officer. He brings a […]
Biotech innovation in Spain: the European Investment Bank provides €20 million in financing to Sanifit to develop treatments for vascular calcification
The EU bank will support Palma-based Sanifit in its work to develop cutting-edge solutions in biomedical research. The venture debt operation is supported by the Investment Plan for Europe. Palma, Spain and San Diego, USA, 6 August 2020 – The European Investment Bank (EIB) is set to support the development of new treatments […]
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical […]
Latest News
UPCOMING EVENTS
17th – 19th November – Jefferies London Healthcare Conference, London, UK.
14th – 16th November – American Heart Association Conference, Dallas, USA.
26th – 28th October – BIO Europe, Munich, Germany
20th – 25th October – ASN Kidney Week, Denver, USA